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Abstract
 
Although the primary function of the DNA mismatch repair (MMR) system is to identify and
correct base mismatches that have been erroneously introduced during DNA replication, recent
studies have further implicated several MMR components in somatic hypermutation of immuno-
globulin (Ig) genes. We studied the immune response in mice deficient in MutS homologue
(MSH)3 and MSH6, two mutually exclusive partners of MSH2 that have not been examined
 
previously for their role in Ig hypermutation. In 
 
Msh6
 
2
 
/
 
2
 
 and 
 
Msh3
 
2
 
/
 
2
 
/
 
Msh6
 
2
 
/
 
2
 
 mice, base sub-
stitutions are preferentially targeted to G and C nucleotides and to an RGYW hot spot, as has
been shown previously in 
 
Msh2
 
2
 
/
 
2
 
 mice. In contrast, 
 
Msh3
 
2
 
/
 
2
 
 mice show no differences from
their littermate controls. These findings indicate that the MSH2–MSH6 heterodimer, but not the
MSH2–MSH3 complex, is responsible for modulating Ig hypermutation.
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Introduction
 
Somatic mutation of Ig V region genes contributes to the
generation of antibody diversity and is required for the pro-
duction of high-affinity neutralizing antibodies (1). In the
process of V region hypermutation, single base changes and
occasional deletions and insertions are introduced into rear-
ranged V regions and their immediate flanking sequences at
extremely high rates of 10
 
2
 
3
 
–10
 
2
 
4
 
/bp/generation (1–3). The
mutations exhibit a characteristic pattern of hot spot selec-
tion and nucleotide substitutions (4–6), yet the mechanism
by which these base changes are introduced remains a puz-
zle (7). Considering the high rate and substrate of muta-
tion, it seems likely that normal mechanisms of DNA repair
might play a direct role in the mutational process or sec-
ondarily affect its outcome (8). Studies of mice and patients
who lack components of the nucleotide or base excision
repair pathways have not revealed abnormalities in V region
mutation (for a review, see reference 9). However, several
groups have recently shown that MutS homologue (MSH)2,
postmeiotic segregation (PMS)2, and MutL homologue
(MLH)1, three components of the DNA mismatch repair
(MMR) system, may be involved (8, 10–15).
The primary function of the MMR system is to identify
and correct base mismatches introduced during semiconser-
vative DNA synthesis. Postreplicative MMR is best charac-
terized in bacteria, where MutS first recognizes the mis-
matched DNA site, then recruits MutL, which in turn binds
and activates the MutH endonuclease. A DNA oligonucleo-
tide containing the mismatch is then excised, and a patch
roughly 200 nucleotides in length is then resynthesized cor-
rectly by DNA polymerase III (16). In yeast and higher eu-
karyotes, the initiation of MMR is thought to require com-
plexes between subsets of the three MutS homologues,
MSH2, MSH3, and MSH6. A complex of MSH2 and
MSH6 is required for the repair of single nucleotide muta-
tions, whereas a complex of MSH2 and MSH3 is required for
2–4 bp mutations, although there may be some redundancy
in these functions. In a subsequent step, the MLH1–PMS2
heterodimer is recruited, and ultimately the mismatch-con-
taining DNA is excised and resynthesized correctly (17).
Previous studies of MSH2-deficient mice revealed that V
region mutations were preferentially targeted to G and C nu-
cleotides and to hot spot motifs (8, 11, 12). Although earlier
studies did not show selective targeting to G and C in PMS2-
or MLH1-deficient mice (8, 13, 18), a more recent study, in
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which a passenger L chain transgene contained an artificial
target within its V region, did reveal that G and C were also
preferentially targeted in PMS2- and MLH1-deficient mice
(14). The overall frequency of mutations during the primary
response was similar in the 
 
Msh2
 
2
 
/
 
2
 
 and wild-type mice.
There was a decrease in the accumulation of base changes in
chronically immunized Peyer’s patch B cells (11, 12).
We present here our studies on V region hypermutation
in mice genetically deficient in the MSH3 and MSH6
components of the MMR system, two proteins that have
not been examined previously for their role in the immune
response. Our studies reveal that 
 
Msh6
 
2
 
/
 
2
 
 and 
 
Msh3
 
2
 
/
 
2
 
/
 
Msh6
 
2
 
/
 
2
 
 mice resemble the 
 
Msh2
 
2
 
/
 
2
 
 mice, in that V region
mutations are primarily targeted to G and C nucleotides and
are focused in RGYW hot spots. Furthermore, although the
mutation frequency is unchanged in the splenic primary re-
sponse, fewer base changes accumulate in Ig genes of
chronically stimulated Peyer’s patch germinal center (GC)
cells. In contrast, the frequency and characteristics of V re-
gion mutation in 
 
Msh3
 
2
 
/
 
2
 
 mice are the same as in their wild-
type or heterozygous littermates. Taken together with the
earlier studies on 
 
Msh2
 
2
 
/
 
2
 
 mice, these results indicate that
in B cells, the MSH2–MSH6 complex and additional down-
stream factors are collectively responsible for the balance of
mutations between G/Cs and A/Ts. These studies thus
confirm that MMR plays a role in the outcome of V region
hypermutation, and extend our knowledge of the individ-
ual factors that are involved.
 
Materials and Methods
 
MMR-deficient Mice. 
 
Mice deficient in MSH6 and MSH3
were generated previously (19, 20). Single-knockout 
 
Msh6
 
 and
 
Msh3
 
 mice (129/Sv 
 
3
 
 C57BL/6 
 
3
 
 SJL) were backcrossed to
C57BL/6 for four to six generations before use. Mice deficient in
both MSH3 and MSH6 were obtained by breeding 
 
Msh3
 
2
 
/
 
2
 
 mice
to 
 
Msh6
 
2
 
/
 
2
 
 mice that had been backcrossed twice to C57BL/6.
Mice were prescreened for IgH
 
b
 
 allotype before use. In all cases,
MMR-deficient animals were analyzed in parallel with wild-type
or heterozygous sex-matched littermate controls, so that any resid-
ual mouse strain background or environmental differences would
be controlled for in each analysis. All mice were maintained in spe-
cific pathogen-free housing in microisolator cages.
 
Mouse Immunization. 
 
4-hydroxy-3-nitrophenyl (NP) conju-
gated to chicken 
 
g
 
-globulin (CGG) at a ratio of 17:1 was pur-
chased from Biosearch Technologies. Mice 8–12 wk old that were
free of obvious disease were given a primary immunization with 50
 
m
 
g of alum-precipitated NP
 
17
 
-CGG via the intraperitoneal route
(21). Mice were tail-bled at weekly intervals, and then boosted in-
traperitoneally with 100–200 
 
m
 
g NP
 
17
 
-CGG in PBS. Spleens were
obtained 10 d after the primary immunization or 4 d after the boost.
 
Isolation of B Cells. 
 
Single cell suspensions of either spleen or
Peyer’s patch lymphocytes were sequentially incubated with
anti–mouse CD45R (B220), MACS MicroBeads (Miltenyi Bio-
tec), phycoerythrin-labeled anti–mouse CD45R (B220) antibody
(GIBCO BRL), and fluorescein-labeled peanut agglutinin (Vector
Labs). After binding to a MACS VS
 
1
 
 column, the B220
 
1
 
 fraction
was separated by FACS
 
®
 
 (FACStar
 
PLUS™
 
; Becton Dickinson),
yielding 90–95% pure B220
 
1
 
 peanut agglutinin–high cells. Ge-
nomic DNA was processed as described (22).
 
PCR Amplification of Ig Sequences. 
 
Anti-NP V regions (V186.2
and V3 gene families) rearranged to J
 
H
 
1 and J
 
H
 
2 segments were
amplified by nested PCR using published primers as the outer
pair (21). The nested forward primer had the sequence 5
 
9
 
-CAG
GTC CAA CTG CAG CAG C-3
 
9
 
, with reverse primer sequence
5
 
9
 
-TGA GGA GAC GAT GAC CGT GG-3
 
9
 
. Cycling parame-
ters were 30 cycles of 45 s at 95
 
8
 
C, 45 s at 61
 
8
 
C, and 3 min at
72
 
8
 
C for the first round. In the second round, 1/50 of the PCR
product was amplified for another 30 cycles of 45 s at 95
 
8
 
C, 45 s
at 55
 
8
 
C, and 2 min at 72
 
8
 
C (Perkin-Elmer Corp.). The fidelity of
 
Pfu
 
 DNA polymerase was verified by sequencing V regions from
splenic peanut agglutinin–low B220
 
1
 
 cells, yielding a mutation
frequency of 1.81 
 
3 
 
10
 
2
 
4
 
/bp (5 mutations in 27,636 bp). J
 
H
 
4
flanking regions were amplified according to the methods of Frey
et al. (11), except that restriction site sequences were omitted
from the primers. Only J
 
H
 
4 segments from genes with unique re-
arrangements were analyzed. PCR products were cloned into the
Bluescript vector (Stratagene) and sequenced (ABI 377; Applied
Biosystems) at the Albert Einstein College of Medicine Sequenc-
ing Facility.
 
Serological Assays. 
 
Sera were screened by ELISA for NP re-
activity using plates coated with 1
 
 
 
m
 
g/ml NP
 
13
 
-BSA to assay the
total response, or 1 
 
m
 
g/ml NP
 
2.5
 
-BSA to detect high affinity anti-
bodies (Biosearch Technologies). Anti-NP antibodies were de-
tected with goat anti–mouse IgM or IgG
 
1
 
 (Southern Biotechnol-
ogy Associates). Sera were plated at an initial dilution of 1:100,
then serially diluted to 1:102,400. The titer was assigned at one
half the maximum absorbance, measured at 405 nm.
 
Statistical Analysis. 
 
To assess the statistical significance of hot
spot targeting in mutated V regions, the frequency of clones con-
taining a mutation in the G92 hot spot was compared with the
frequency of mutated clones lacking this RGYW hot spot muta-
tion, using the 
 
x
 
2
 
 and Fisher’s exact tests. The frequency of mu-
tated clones was also compared with the frequency of unmutated
V regions recovered, using the same statistical tests. For the statis-
tical analysis of anti-NP IgG
 
1
 
 titers, the two-sample 
 
t
 
 test and the
Wilcoxon rank sum test were both carried out, using the titer
measured in each mouse as the input. Both tests yielded compara-
ble results. All statistical analyses were performed with StatXact
v4.0 (Cytel Software Corp.).
 
Results
 
Mutation Frequency in Ig Genes of MMR-deficient Mice.
 
Mice lacking MSH3 or MSH6 were challenged with the hap-
ten NP, and GC B cells from the spleen were analyzed 10 d
after primary immunization. The proportion of mutated V
regions and the frequency of base changes in 
 
Msh3
 
2
 
/
 
2
 
,
 
Msh6
 
2
 
/
 
2
 
, and 
 
Msh3
 
2
 
/
 
2
 
/
 
Msh6
 
2
 
/
 
2
 
 mice were not signifi-
cantly different from each other (Table I). In addition, mu-
tation frequencies in each of these gene-targeted mice were
indistinguishable from those observed in their respective
littermate controls during the early primary response. Our
results are consistent with those reported by others for MSH2-
and PMS2-deficient mice (8, 11, 12, 18). Collectively, the
data suggest that these defects in MMR do not greatly af-
fect the frequency of somatic mutation when B cells have
undergone relatively few rounds of replication and muta-
tion. 
 
Msh6
 
2
 
/
 
2
 
 mice were also examined 4 d after secondary
immunization (Table I). In the 
 
Msh6
 
2
 
/
 
2
 
 mice, a signifi-
cantly lower proportion of the V regions contained muta- 
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tions (
 
P
 
 , 
 
0.015), yielding fivefold fewer mutations over-
all. However, the frequency of base changes in those few V
regions that did mutate was not statistically different be-
tween 
 
Msh6
 
2
 
/
 
2
 
 and 
 
Msh6
 
1
 
/
 
1
 
 mice.
Since B cells in the intestinal Peyer’s patches are con-
stantly responding to a wide variety of gut antigens rather
than to one specific immunogen, many different V regions
are being mutated. Mutation in these different V regions
can be analyzed by examining the noncoding intronic se-
quence flanking a rearranged J
 
H
 
4 segment, using the PCR
strategy developed by Jolly et al. (23). Using this approach
in slightly modified form, Frey et al. (11) observed three-
fold and fivefold decreases in mutation frequency in the
Peyer’s patch GC B cells of 
 
Pms2
 
2
 
/
 
2
 
 mice and 
 
Msh2
 
2
 
/
 
2
 
mice, respectively. Rada et al. (12) independently observed
a fivefold reduction in mutation frequency in 
 
Msh2
 
2
 
/
 
2
 
mice compared with their littermate controls.
As shown in Table II, J
 
H
 
4 flanking regions from the
Peyer’s patches of 
 
Msh6
 
2
 
/
 
2
 
 mice exhibit a decrease in mu-
tation frequency, which, although not statistically signifi-
cant, is similar to the findings of other researchers for
Pms22/2 mice (10, 11). For the Msh32/2 mice, we had a
larger number of sequences to analyze than in Table I, and
the frequency of mutation was statistically indistinguishable
from their Msh31/1 littermates, as assessed with the two-
tailed Fisher’s exact test. This indicates that even after many
rounds of cell replication, the loss of MSH3 does not affect
the frequency of V region mutation. In contrast, mice defi-
cient in both MSH3 and MSH6 have fewer mutated V re-
gions (P , 0.037), and a lower frequency of mutations in
Table I. Mutation Frequency in the Anti-NP Response
V sequences analyzed Mutation frequency (31023)
Total No. of
sequences
Percent mutated
sequences
Total No. of
mutations All sequences
Mutated
sequences
Primary response
Msh32/2 35 71 91 9.3 13.0
Msh31/2 5 80 16 11.4 14.3
Msh62/2 16 69 36 8.0 12.0
Msh61/2 27 59 36 4.8 8.0
Msh32/2/Msh62/2 30 50 30 3.6 7.1
Msh31/2/Msh61/2 11 29 20 6.5 17.9
Secondary response
Msh62/2 22 5 1 0.2 3.6
Msh61/2 14 43 12 3.1 7.1
Canonical V186.2 mutated regions and V186.2 analogues have been included in this analysis.
Table II. Mutation Frequency in JH4 Flanking Regions from Peyer’s Patch GC B Cells
V sequences analyzed Mutation frequency (31023)
Total No. of
sequences
Percent mutated
sequences
Total No. of
mutations All sequences
Mutated
sequences
Msh32/2* 11 36 17 5.9 16.3
Msh31/2 10 30 13 5.0 16.6
Msh62/2 18 22 7 1.5 6.7
Msh61/1 8 14 4 1.9 15.4
Msh32/2/Msh62/2 14 14 2 0.5 3.8
Msh31/2/Msh61/2 6 66 19 12.2 18.3
*Peyer’s patches from two to three litter-matched mice were pooled within each genotype.582 V Region Mutation in MSH3- and MSH6-deficient Mice
those few V regions that are mutated, than their heterozy-
gous littermates. In these Msh32/2/Msh62/2 mice, the pro-
portion of mutated JH4 regions and the mutation frequency
are also lower than in the Msh32/2 and Msh62/2 single-
knockout mice (Table II).
The Anti-NP Humoral Response in MMR-deficient Mice.
To evaluate whether these small differences in the frequency
of mutation were associated with detectable changes in the
immune response, we measured anti-NP Ig serum levels
and examined the B and T cell compartments in MMR-
deficient mice. Mice lacking MSH3 alone responded to
NP immunization in a manner statistically indistinguishable
from that of their littermates. In contrast, in Msh62/2 mice,
IgG1 anti-NP titers were at one half the level measured in
wild-type littermates in both the primary (P , 0.008) and
secondary (P , 0.032) response (data not shown). Mice
lacking both MSH3 and MSH6 also had significantly lower
titers of anti-NP IgG1 at day 21 of the primary response (P ,
0.015), with titers at one quarter the levels observed in lit-
termate controls. The average affinity, as measured by the
titer of IgG1 binding low-substituted NP-BSA, was also
depressed. Similar decreases in hapten-specific IgG1 anti-
bodies have been reported in MSH2-, PMS2-, and MLH1-
deficient mice (11, 12, 24–26). Since hapten-specific IgM
levels were normal in all of the mice tested, the lower level
of IgG1 may be due to a switching defect (25, 26) or ge-
netic instability caused by a deficiency in MMR in mem-
ory B or T cells that have undergone many rounds of repli-
cation (11, 24). We detected no gross defects in the number
or maturation of peripheral T cell subsets in spleen or
Peyer’s patches in any of the MMR-deficient mice (data
not shown). There was a moderate decrease in the absolute
and relative number of CD45R1 B cells in the spleens of
Msh32/2/Msh62/2 mice, whereas Msh3 or Msh6 single-
mutant mice showed no difference compared with wild-
type controls (data not shown). In addition, we observed
fewer mature B cells in both the bone marrow and spleens
of Msh32/2/Msh62/2 mice (data not shown), as has been
reported in MSH2-deficient mice (24).
Targeting to G and C Bases and to Hot Spots in MMR-defi-
cient Mice. In MSH3-deficient mice, the spectrum of mu-
tations was very similar and not significantly different from
their heterozygous littermates (Table III). In contrast,
Msh62/2 mice resembled Msh22/2 mice, in that 100% of
mutations in the V regions from splenic B GC cells oc-
curred in G or C, compared with 67% for the Msh61/2 lit-
termates (Table III). The difference in the targeting of A
and T nucleotides was significant at P , 0.0004. For
Msh32/2/Msh62/2 mice, 95% of mutations were in G and C,
compared with 67% in the double-heterozygote litter-
mates, and the differences in the proportion of mutations in
A and T were significant at P , 0.004. When we included
the base substitutions recovered from JH4 regions (Peyer’s
patches), there were a few additional mutations in A and T,
but the vast majority of the mutations were still in G and C
bases (Fig. 1). As shown in Table III, there is a strong bias
for transitions over transversions, a hallmark of somatic hy-
permutation. Thus, mice lacking MSH2, MSH6, or both
MSH3 and MSH6 show a skewed targeting for G and C,
whereas Msh32/2 mice exhibit a normal pattern of base
substitutions. The results reported here complement and
Table III.  Base Substitutions in Mutated V Regions from Splenic 
GC B Cells
Primary and secondary anti-NP responses in Msh32/2 and Msh62/2
mice are pooled in this analysis.
*The total number of mutations analyzed in each data set is indicated as n.
Figure 1. G and C nucleotides are preferentially mutated in Msh62/2
and Msh32/2/Msh62/2 mice, but not in Msh32/2 or in heterozygous
mice. The proportions of mutations in G and C bases, relative to those
targeting A and T bases, are expressed as a percentage of the total muta-
tions and are depicted as black and white bars, respectively. As discussed
in the text, mutations in A and T are significantly fewer in Msh62/2 and
Msh32/2/Msh62/2 mice, compared with Msh32/2 or wild-type control
mice. Base substitutions collected from both spleen and Peyer’s patch GC
B cells are combined in this figure. Results from heterozygous littermates
of all three genotypes are pooled in this figure; details of each MMR lit-
termate control can be found in Tables I–III. The wild-type sample rep-
resents data from Msh61/1 control mice. These sequence data are avail-
able from GenBank under accession nos. AF183260–AF183322.583 Wiesendanger et al. Brief Definitive Report
extend the observations published by others on the MSH2,
PMS2, and MLH1 proteins (8, 10–14, 18).
Rada et al. (12) have also shown that in MSH2-deficient
mice, the base substitutions are clustered in a relatively
small number of hot spots. In agreement with the findings
of others who have studied the NP response (21, 27, 28),
we found that the RGYW hot spot at base 92 and codon
31 exhibited a high frequency of mutations. This hot spot
accounts for 17 and 24% of the mutations in Msh62/2 and
Msh32/2/Msh62/2 mice, and preferential mutation at this
position is significantly different between the null mice and
their littermates (P , 0.02 and P , 0.003, respectively). In
contrast, mutations at the G92 hot spot accounted for only
4% of the mutations in Msh32/2 mice, and were not signif-
icantly different from the wild-type control sample (7%).
Discussion
Since MSH2 dimerizes with MSH3 or MSH6, we were
interested in whether the lack of either one of these mole-
cules would differentially affect V region hypermutation.
The phenotypes of the MSH3 and MSH6 single-mutant
mice are quite different (19, 20). Msh62/2 mice have a re-
duced life span and an increased susceptibility to cancer,
whereas Msh32/2 mice have neither a decrease in survival
nor a significant increase in cancer risk. Nuclear extracts
derived from the Msh62/2 mice are deficient in the repair
of single base mismatches, but are proficient in the repair of
single base insertions and dinucleotide insertions and dele-
tions. In contrast, Msh32/2 extracts are proficient in the re-
pair of single base mismatches and certain types of single
base insertions, but are deficient in the repair of dinucle-
otide insertions and deletions. In the studies reported here,
we have shown that the loss of MSH3 does not have a de-
tectable effect on the characteristics or frequency of V re-
gion mutation. In contrast, the absence of MSH6 results in
the restriction of mutations to G and C in some hot spots,
as has been reported for the Msh22/2 mice (8, 12, 29). In
addition, the absence of both MSH3 and MSH6 has a sim-
ilar effect as the loss of either MSH6 or MSH2. These re-
sults suggest that the mismatches that are created during the
primary process of V region mutation in B cells are recog-
nized by the MSH2/MSH6 dimer, rather than by the
MSH2/MSH3 complex. This is consistent with the fact
that most of the somatic mutations that have been observed
in normal mice are single base changes. The increase in tu-
mor load, the earlier onset of tumors, and the apparently
greater decrease in the frequency of mutation in the Peyer’s
patch GC cells of the Msh32/2/Msh62/2 mice reported here
collectively suggest that there may be a role for MSH3, at
least in the absence of MSH6, and that it is expressed in
GC B cells.
Somatic hypermutation was studied in NP-immunized
mice, as this hapten elicits a well-studied immune response
in C57BL/6 mice, where the V186.2 gene and close rela-
tives thereof, termed analogues, play a predominant role
(27, 28). The NP response of mice lacking both MSH3 and
MSH6 is atypical in that we recovered very few canonical
V186.2 regions (7% of the mutated V regions). This was not
observed in the Msh32/2 mice, where the canonical V186.2
region, along with the affinity-enhancing W33L mutation,
was recovered from 74% of the mutated VDJ rearrange-
ments. In Msh62/2 mice, 55% of the mutated anti-NP re-
arrangements contained the V186.2 gene. One explanation
for the low representation of V186.2 in the double-mutant
mice is that they were incompletely backcrossed to C57BL/6,
unlike the Msh3 and Msh6 single mutants.
There is no simple explanation for why there should be a
selective decrease in A and T mutations in MSH2- and
MSH6-deficient mice. One possibility is that V region hy-
permutation occurs as a series of separable events, and that
the processes that cause mutation in G and C are different
from those that target A and T. One example of such a model
is that MMR is not involved in the primary mutational
event that affects primarily G and C, but MSH2 and its as-
sociated proteins do recognize the mismatches created by
that initial mutagenic event, and in the course of repairing
them, mutations are introduced in A and T bases (12). It is
intriguing that mutational targeting to G and C bases is an
intrinsic feature of mutation in lower vertebrates and in hy-
permutating cell lines (30–32). Although the consensus is
that MMR is not involved in the primary mutational
event, Cascalho et al. (10), Wilson et al. (3), and Kong and
Maizels (15) have suggested that MMR may play a primary
role in the mutation process.
In conclusion, the studies reported here confirm a role
for MMR in the outcome of the process of V region
hypermutation. They show that in addition to MSH2,
MLH1, and PMS2, MSH6 plays a role in this event. Al-
though they do not eliminate the possibility that one or
more of the MMR proteins play a direct role in the muta-
tional process, they are consistent with the proposal that
the initial target of the mutational process is single base
changes in G or C, and that the mutations in A and T are
the result of a subsequent error-prone repair process (8, 12).
Although we do not know what proteins are responsible
for the primary mutational event, these studies indicate that
MSH6 is among the transacting proteins that are required
for the mutational process.
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